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INTRODUCTION
Asthma is a chronic inflammatory disease of the lungs causing increased airways reactivity to various stimuli. Allergy and asthma are indicators of altered immune system dynamics and an excessive inflammatory response (1) . A number of studies have investigated asthma and allergies, including hay fever, eczema, and allergies to medications, as risk factors for cancer, often as part of comprehensive investigations on other risk factors (2) . Generally, allergies seem to be associated with a decreased risk of pancreatic cancer (2, 3) and nonHodgkin lymphoma (4) while the observed association between a history of asthma and increased risk of lung cancer might be due to confounding by smoking (2) .
Inflammation is considered an important pathway for prostate carcinogenesis (5) and it is possible that men with a hyperactive immune system that produces excessive inflammatory responses are at increased risk of prostate cancer.
A recent meta-analysis of the few studies that have investigated the association between atopy and prostate cancer risk (assessed by allergen-specific IgE or skin prick testing) reported evidence of a modest association (6) . The same meta-analysis reported
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Copyright © 2010 American Association for Cancer Research previous medical conditions. Participants were first asked whether a doctor had ever told them that they had asthma or wheezy breathing. Those who responded affirmatively were asked the age at diagnosis and whether the condition required medications. Subjects completed a dietary questionnaire that was also used to calculate nutrients and energy intake (7) . Body mass index was calculated from measured height and weight while fat and fat-free mass were derived from measured resistance and reactance (8) . 
Medication audit at baseline
At baseline, participants were asked to bring all their current medications were taking to the study center where the interviewer recorded the name of each medication on a form specifically designed for this purpose. One of the authors (MA) a specialist physician in respiratory medicine, coded medications that may be used to treat or prevent asthma into four groups: antihistamines, bronchodilators, inhaled glucocorticoids, and systemic glucocorticoids that include mainly tablets and injections. Some men reported using glucocorticoids in the form of creams, ointments, and drops possibly prescribed for various skin disorders like dermatitis and psoriasis and for inflammation of the eye. These medications were coded in a separate group labeled "topical glucocorticoids". There were 2,969 (18%) men who did not complete the medication audit, and were, therefore, excluded from analyses of baseline medication use.
Statistical Analysis
Follow-up began at baseline and continued until diagnosis of prostate cancer or cancer of unknown primary site, death, date left Australia, or end of December 2007, whichever came first. Cox regression with age as the time axis was used to derive adjusted hazard ratios for men in each category of exposure. Men with asthma were categorised in two groups according to age at diagnosis using the median in the full cohort as cut-off value.
All final analyses included country of birth as a covariate with four categories (i.e.
Australia, UK, Greece, and Italy). Further adjustment for other potential confounders including education, body mass index, fat and fat-free mass, smoking, alcohol consumption, and total energy intake did not materially change the estimated rate ratios. Cox regression models based on competing risks were fitted using a data duplication method to test the heterogeneity in the rate ratios between aggressive and non-aggressive cancer (10) . These analyses were performed stratifying the Cox models for type of outcome (aggressive or non-aggressive prostate cancer) thus allowing the hazard function associated with the two types of failure to be different.
The association of prostate cancer risk with group of medication that can be used to treat asthma was estimated from the data obtained at the drug audit using a Cox regression model with and without adjusting for reported history of asthma. The data from the men who completed the drug audit were also used to investigate whether the association with asthma changed after adjustment for the use of different groups of medications.
A sensitivity analysis to investigate the effect of prevalent cancers (i.e. prostate cancer present but not diagnosed at baseline) on the association between asthma and asthma medications and prostate cancer risk was performed by excluding the first two years of follow-up.
Statistical analyses were performed using Stata 10.1 (Stata Corporation, College Station, TX). The likelihood ratio test was used to test hypotheses whenever possible. The Wald test was used to test differences in the hazard ratios by age at diagnosis and use of medications to control asthma.
RESULTS
From the 16 934 men eligible for the study, we identified 1 179 prostate cancers, and this prevalence ranged from 12% for men born in Australia to 7% for men born in Italy or Greece. The median age at diagnosis of asthma was 32 years, with one quarter diagnosed during childhood (before their 10th birthday) and one quarter in late adulthood (50 years of age or above). Two thirds (67%) of asthmatic men reported using medications to control the disease and this proportion was higher for men diagnosed at an older age (> 32 years, 77%) than for men diagnosed at an earlier age (≤ 32 years, 59%, P < 0.001).
Overall, asthma was associated with an increased risk of prostate cancer (P = 0.02, Table   2 ). The increase in risk of prostate cancer for men with a history of asthma compared with men without such a history was small but significant (HR 1.25, 95% CI = 1.05 to 1.49).
The HR for men who used medications to control asthma (1.29, 95% CI = 1.05 to 1.58) was not significantly different from the HR for men who did not use medications to control asthma (1.12, 95% CI = 0.81 to 1.54, Wald test for the difference P = 0.46). Similarly, the HR for men who reported a history of asthma diagnosed at an older age (1.29, 95% CI = 1.03 to 1.63) was not significantly different from the HR for men who reported a history of asthma diagnosed at an early age (1.17, 95% CI = 0.90 to 1.54, Wald test for the difference P = 0.58). The HR associated with asthma for non-aggressive prostate cancer (1.33, 95% CI = 1.08 to 1.63) was not significantly different from the HR for aggressive prostate cancer (1.08, 95% CI = 0.76 to 1.54, P for heterogeneity = 0.32).
The proportions of participants using inhaled glucocorticoids, systemic glucocorticoids, antihistamines, or bronchodilators at baseline were 3%, 1%, 2%, and 5% respectively. The 
DISCUSSION
We found that a reported history of asthma and the use of some medications to treat or prevent asthma, particularly systemic glucocorticoids, was associated with an increased prostate cancer risk. Registries in Australia). The information on asthma and use of medications was collected at baseline so it was unlikely that bias due to differential recall occurred. Also, questions on self-reported physician-diagnosed asthma, like the ones we used, have been found to be highly specific and more reliable than symptom-based questions or questionnaires asking respondents if they have ever had asthma (11, 12) .
One limitation of this study was the lack of information on the type of asthma and its natural history. We did not collect information on coexisting allergies like allergic eczema and rhinitis, allergy to house dust mite, or allergy to medications. We were, therefore, unable to distinguish between allergic asthma and non-allergic, or intrinsic, asthma (13, 14) , a distinction that might have helped in interpreting our results.
Studies that have investigated possible associations between asthma or allergies and prostate cancer risk are few. Two American cohort studies, one of members of the Seventhday Adventist church in California (15) and one of participants in the National Health and Nutrition Survey (NHANES I)(16), examined the risk of different types of cancer associated with self-reported asthma and found no association with prostate cancer as did a Finnish study that compared cancer incidence in a cohort of asthmatic men with the incidence in the general population (17) . A more recent study of 1 552 men in Busselton, Western Australia (18), including 86 prostate cancer cases, reported an association between allergy to house dust mite, determined using skin-prick testing, and increased risk of prostate cancer (HR 2.90, 95% CI = 1.26 to 6.68). This study also reported suggestive evidence that men who reported a history of asthma had a higher risk of prostate cancer (HR 1.89, 95% CI = 1.00 to 3.60). With the exception of the Finnish study that was based on 256 prostate cancer cases, the estimates from all these studies were based on a small Despite our study having limited statistical power to detect modest to moderate differences in the hazard ratios by prostate cancer aggressiveness, our results did not provide evidence that the observed associations were limited to non-aggressive prostate cancer. This suggests that these associations are unlikely to be an artefact due to confounding with PSA testing. A possible explanation for the association between asthma and prostate cancer risk is that chronic or excessive immune stimulation leads to malignant transformations. Although a local inflammatory process in the respiratory system is unlikely to affect the behaviour of the cells in the prostate per se, it might be an indicator of a general propensity of the immune system to overreact to antigens. An alternative explanation is that asthma does not increase prostate cancer risk per se but through the use of medications. Indeed it is difficult to disentangle the effects due to asthma itself from those due to medications for asthma as the two factors are strongly correlated.
We found suggestive evidence that asthmatic men who reported taking medications for their asthma have slightly higher risk of prostate cancer than those asthmatic men who reported not taking medications specifically for asthma. If this difference exists, it suggests that more severe asthma and inflammation could be more strongly associated with risk of prostate cancer than mild asthma. Further research is needed to investigate this possibility.
Of all medications potentially used for asthma, systemic glucocorticoids showed the strongest association with prostate cancer risk. This association remained statistically the number of prescriptions of glucocorticoids was associated with an increased risk of squamous cell carcinoma and basal cell carcinoma of the skin, and non-Hodgkin lymphoma (22) . None of these studies were prospective cohorts and, to our knowledge, no prior studies have examined risk of prostate cancer in relation to glucocorticoid use.
The observed associations need to be confirmed by independent prospective studies.
Further studies are needed to clarify the possible mechanisms underlying these associations. The analysis of asthma was based on 16 934 men including 1 179 prostate cancer cases. The analysis of medications from the drug audit was based on 13 965 men including 1 007 prostate cancer cases (2 797 men did not participated to the drug audit). 3 Estimates from the Cox regression including tumour aggressiveness as stratum. The analysis of asthma was based on 16 924 men, including 840 non aggressive and 329 aggressive prostate cancers. Ten cases were excluded because we were not able to define aggressiveness. The analysis of medications from the drug audit was based on 13 956 men, including 709 non aggressive and 289 aggressive prostate cancers. 4 Likelihood ratio test comparing a full model to a model excluding the given variable(s).
5
Subjects who reported clinician diagnosed asthma were asked whether they used medications to treat their asthma. 6 Test of heterogeneity in the hazard ratios between aggressive and non-aggressive tumours. 7 Medications that may be used to treat or prevent asthma reported at the baseline medication audit. HRs associated with taking versus not taking specified medications. 
